Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/34761
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Coleções
Metadata
Mostrar registro completo
ARTEMISININ-(ISO)QUINOLINE HYBRIDS BY C-H ACTIVATION AND CLICK CHEMISTRY: COMBATING MULTIDRUG-RESISTANT MALARIA
Artemisinina
Resistência a medicamentos
Hibridização
Proteomica
Malaria
Autor(es)
Afiliação
Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials. Erlangen, Germany.
Georg-August-Universit Gottingen. Institut fur Organische und Biomolekulare Chemie. Gottingen, Germany.
Georg-August-Universit Gottingen. Institut fur Organische und Biomolekulare Chemie. Gottingen, Germany.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Institute of Chinese Materia Medica. Artemisinin Research Center. China Academy of Chinese Medical Sciences. Beijing, China.
Institute of Chinese Materia Medica. Artemisinin Research Center. China Academy of Chinese Medical Sciences. Beijing, China.
Institute of Chinese Materia Medica. Artemisinin Research Center. China Academy of Chinese Medical Sciences. Beijing, China.
National University of Singapore. Department of Biological Sciences. Singapore, Singapore.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Shenzhen People’s Hospital. Shenzhen, China.
Georg-August-Universit Gottingen. Institut fur Organische und Biomolekulare Chemie. Gottingen, Germany.
Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials. Erlangen, Germany.
Georg-August-Universit Gottingen. Institut fur Organische und Biomolekulare Chemie. Gottingen, Germany.
Georg-August-Universit Gottingen. Institut fur Organische und Biomolekulare Chemie. Gottingen, Germany.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Institute of Chinese Materia Medica. Artemisinin Research Center. China Academy of Chinese Medical Sciences. Beijing, China.
Institute of Chinese Materia Medica. Artemisinin Research Center. China Academy of Chinese Medical Sciences. Beijing, China.
Institute of Chinese Materia Medica. Artemisinin Research Center. China Academy of Chinese Medical Sciences. Beijing, China.
National University of Singapore. Department of Biological Sciences. Singapore, Singapore.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Friedrich-Alexander University of Erlangen-N rnberg. Institute of Medical Biotechnology. Erlangen, Germany.
Shenzhen People’s Hospital. Shenzhen, China.
Georg-August-Universit Gottingen. Institut fur Organische und Biomolekulare Chemie. Gottingen, Germany.
Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials. Erlangen, Germany.
Resumo em Inglês
A substantial challenge worldwide is emergent drug resistance in malaria parasites against approved drugs, such as chloroquine (CQ). To address these unsolved CQ resistance issues, only rare examples of artemisinin (ART)-based hybrids have been reported. Moreover, protein targets of such hybrids have not been identified yet, and the reason for the superior efficacy of these hybrids is still not known. Herein, we report the synthesis of novel ART-isoquinoline and ART-quinoline hybrids showing highly improved potencies against CQ-resistant and multidrug-resistant P. falciparum strains (EC50 (Dd2) down to 1.0 nm; EC50 (K1) down to 0.78 nm) compared to CQ (EC50 (Dd2)=165.3 nm; EC50 (K1)=302.8 nm) and strongly suppressing parasitemia in experimental malaria. These new compounds are easily accessible by step-economic C-H activation and copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click reactions. Through chemical proteomics, putatively hybrid-binding protein targets of the ART-quinolines were successfully identified in addition to known targets of quinoline and artemisinin alone, suggesting that the hybrids act through multiple modes of action to overcome resistance.
Palavras-chave
AntimaláricosArtemisinina
Resistência a medicamentos
Hibridização
Proteomica
Malaria
Compartilhar